Tech Company Financing Transactions
Aizen Therapeutics Funding Round
Aizen Therapeutics closed a $13 million venture capital round on 11/21/2024. Investors included Cercano Management and Madrona Venture Group.
Transaction Overview
Company Name
Announced On
11/21/2024
Transaction Type
Venture Equity
Amount
$13,000,000
Round
Undisclosed
Investors
Madrona Venture Group (Chris Picardo)
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
9276 Scranton Rd 500
San Diego, CA 92121
USA
San Diego, CA 92121
USA
Phone
Undisclosed
Website
Email Address
Overview
Aizen is an AI-driven biotechnology company pioneering Mirror Peptides, a novel class of biologic medicines. Mirror Peptides are synthetic, fully D-amino acid peptides that represent a vast, unexplored therapeutic chemical space that provide enhanced therapeutic stability and reduced exogenous immunogenicity for patients.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Todd Peterson
Chief Executive Officer
Ajay Kshatriya
Vice President
Dillon Phan
VP - Bus. Development
Luke Ursell
Browse more venture capital transactions:
Prev: 11/21/2024: Crown Affair venture capital transaction
Next: 11/21/2024: Zepto venture capital transaction
Share this article
News on VC Transactions
We do our best to report on all VC transactions involving tech companies. VC transactions reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs